Thymalin

Thymalin is a peptide preparation obtained by extracting and fractionating calf (bovine) thymus tissue. It is supplied in Russia as a lyophilized powder for injection. The critical point for anyone reading research about it is that thymalin is not one molecule: it is a polypeptide complex, a mixture of short peptides and small polypeptides whose exact composition depends on the extraction and purification process used.

That distinction matters more than it may sound. When a study reports on BPC-157 or on semaglutide, the molecule tested is identical from one laboratory to another. When a study reports on thymalin, the tested material is an extract, and two batches produced under different conditions are not necessarily the same thing. This is the same problem that complicated the interpretation of early Western thymic extracts in the 1970s, before individual thymic peptides were isolated and synthesized.

Work by Morozov and Khavinson reported that specific short peptides could be isolated from the thymalin complex and studied on their own. The best known is the dipeptide Glu-Trp (abbreviated EW), which became the basis of a separate Russian preparation called Thymogen. A second dipeptide, Lys-Glu (KE), is the basis of the preparation marketed as Vilon. Much of the modern mechanistic literature attributed to thymalin is in fact literature on these two dipeptides rather than on the whole extract.

A practical consequence follows. Material sold internationally under the name thymalin by research-chemical vendors has no demonstrated equivalence to the pharmaceutical registered in Russia. It may be a different extract, a synthetic dipeptide blend, or something else entirely, and buyers have no way to verify which. For that reason this guide deliberately contains no dosing information, no reconstitution guidance and no administration protocol.

Educational content only. Thymalin is not an approved medicine in the United States, the European Union, the United Kingdom, Canada or Australia. Consult a qualified healthcare professional for any medical question.

Thymalin emerged from Soviet military medicine. In the 1970s, researchers at the Military Medical Academy in Leningrad, principally Vyacheslav G. Morozov and Vladimir Kh. Khavinson, worked on thymus-derived preparations intended to restore immune function after radiation exposure, burns, trauma, surgery and severe infection. Khavinson later founded the St. Petersburg Institute of Bioregulation and Gerontology, which became the center of this research program.

The timing was not coincidental. The same decade saw intensive Western work on thymic extracts, most famously Allan Goldstein's thymosin fraction 5, from which thymosin alpha-1 and thymosin beta-4 were eventually purified. Soviet and Western groups were chasing the same biological idea from different directions: if the thymus produces factors that drive T-cell maturation, and if the thymus involutes with age, then supplying those factors might partially reverse age-related or stress-related immune decline.

The two research traditions then diverged sharply. Western groups isolated single molecules, synthesized them, and pushed them through conventional regulatory pathways. The Soviet and later Russian program kept the extract in clinical use while also isolating active dipeptides, and it developed a broader theoretical framework that Khavinson called peptide bioregulation: the idea that very short peptides act as regulators of gene expression in specific tissues. The pineal peptide preparation Epithalamin and its synthetic tetrapeptide relative, discussed in our guide to Epithalon, come from the same program.

This history explains an obstacle that frustrates anyone trying to evaluate thymalin today. A large share of the primary literature is in Russian, published in journals with limited international indexing, and available only as English-language abstracts through PubMed. Several decades of clinical reports therefore cannot be read in full, let alone appraised in detail, by most of the international research community.

The core hypothesis is immunomodulation rather than immunostimulation. In the 1997 paper that remains the clearest English-language statement of the mechanism, Morozov and Khavinson reported that both the natural extract and the synthetic dipeptide activated T-cell differentiation and T-cell recognition of peptide-MHC complexes, and altered intracellular cyclic nucleotides and cytokine output of blood lymphocytes. They also reported a difference between the two: the synthetic dipeptide activated neutrophil chemotaxis and phagocytosis but, unlike the natural peptides, had no influence on the antioxidant response in thymocytes. Their framing was that thymic peptides participate in regulating inflammatory processes as cytokine antagonists, which is a very different claim from simply boosting immunity.

The second layer of the hypothesis concerns gene expression. A 2023 paper in the International Journal of Molecular Sciences by Linkova, Khavinson and colleagues used molecular modeling and docking to examine how the EW and KE dipeptides might interact with double-stranded DNA. The authors reported that GGAG was the preferred DNA sequence for EW binding and GCGC for KE, and that cluster analysis pointed to AKT1 and AKT2 as candidate target genes relevant to cytokine storm biology. In the same paper, KE is described as acting on macrophages, blood lymphocytes, thymocytes and neutrophils, while EW is described as reducing angiotensin-induced vasoconstriction and preserving endothelium-dependent vascular relaxation.

That work is worth reading, and it is also worth labeling accurately: it is computational and in vitro reasoning about plausible targets. Docking a dipeptide to a DNA motif in silico is a hypothesis-generating exercise, not a demonstration that the same event occurs in a human lymphocyte at achievable concentrations.

The background biology that makes the hypothesis attractive is real. Thymic involution begins early in life and progresses with age, reducing naive T-cell output and contributing to immunosenescence. A 2020 review by Rezzani and colleagues on the thymus-pineal axis summarizes how the co-involution of these two glands may shape immune and endocrine aging. A compound that genuinely restored thymic output would be a significant advance.

What is missing is the middle of the chain. For thymalin specifically, the international literature contains no published human pharmacokinetics, no dose-response characterization, no biodistribution data and no validated biomarker linking administration of the extract to a defined molecular event in humans. The mechanism is coherent as a story. It has not been closed as a demonstration.

The most cited human report is Khavinson and Morozov's 2003 paper in Neuro Endocrinology Letters. Investigators from the St. Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences assessed thymic (thymalin) and pineal (epithalamin) peptide preparations in 266 elderly and older people over 6 to 8 years. The abstract reports a decrease in mortality rate of 2.0 to 2.1-fold in the thymalin group, 1.6 to 1.8-fold in the epithalamin group and 2.5-fold with both compared with control, and a 4.1-fold decrease in a subgroup that received both preparations in annual courses for 6 years. It also reports a 2.0 to 2.4-fold decrease in the incidence of acute respiratory disease, alongside improvements in cardiovascular, endocrine, immune and nervous system indices.

The second body of human data comes from the COVID-19 period. A Russian-language report in Advances in Gerontology compared severe COVID-19 patients of middle and older age across three groups: basic therapy, basic therapy plus tocilizumab, and basic therapy plus thymalin. Hospital mortality was reported as 40.9 percent, 28.4 percent and 20.6 percent respectively. In the thymalin group the authors described a doubling of lymphocyte and monocyte counts, a 1.3-fold increase in leukocytes, a 1.5-fold increase in platelets, and decreases of 1.2, 1.8 and 1.7-fold in fibrinogen, lactate dehydrogenase and D-dimer.

The rationale for testing it in that setting was laid out separately by Kuznik, Khavinson and Smirnov in a 2021 Advances in Gerontology review, which argued that severe COVID-19 in older patients is driven by innate immunity dysfunction, NLRP3 inflammasome activation and pro-inflammatory cytokine synthesis, with lymphocytopenia and elevated D-dimer among the main risk factors for multiple organ failure and death.

Beyond these, PubMed indexes a long tail of older Russian-language abstracts: effects of thymalin on the thymus and immunological indices in irradiated animals, on immunogenesis and hemostasis in patients with ischemic heart disease, and its use in suppurative-inflammatory processes. These are abstracts, often from the 1980s, usually without accessible full text and without the methodological detail needed for appraisal.

We are not aware of any completed randomized, double-blind, placebo-controlled multicenter trial of thymalin published in a major international journal, nor of any regulatory review of the product by the FDA or the EMA.

This is where a reference guide has to be blunt. The thymalin literature has structural weaknesses that no amount of citation counting fixes.

• Design. The flagship 6 to 8 year study is an open, non-randomized comparison with a control group, not a randomized controlled trial. Without randomization and blinding, differences in baseline health, motivation, follow-up intensity and access to care can easily produce the direction of effect reported.
• Effect size implausibility. A 2.0-fold, let alone 4.1-fold, reduction in all-cause mortality in people over 60 would exceed the effect of every intervention in modern geriatric medicine, including optimal blood pressure control and statins. Extraordinary effect sizes from non-randomized designs are usually a signal about the design, not about the compound.
• Single-group provenance. Most of the positive clinical literature comes from one institute and its collaborators, with the developers of the product as authors. Independent replication outside Russia is essentially absent.
• Reporting. Results are frequently expressed as fold-changes without confidence intervals, without prespecified primary endpoints, and without trial registration, which prevents any assessment of selective reporting.
• Language and access. When the full text cannot be read, peer appraisal cannot happen. English abstracts are not a substitute.
• Product definition. Because the tested material is an extract, even a perfect trial of one batch would leave open how far the result generalizes to other batches or to products sold under the same name elsewhere.

None of this proves thymalin is inert. It means the honest classification is unproven, supported by a mechanistic hypothesis and by decades of national clinical practice, but not by the kind of evidence that would justify confidence in any specific claim. Readers interested in how we grade evidence tiers across this field can compare our discussion in peptides and anti-aging research.

What would change the picture is not mysterious: a preregistered randomized trial, with a characterized and batch-controlled product, blinded outcome assessment, hard clinical endpoints such as infection incidence or hospitalization, conducted at independent sites and published in full. Until something like that exists, thymalin remains a historically interesting preparation with a weak international evidence base.

These three are routinely conflated in online discussion because all three trace back to thymus research, but they are not interchangeable in any meaningful sense.

Thymosin alpha-1 is a defined 28-amino-acid synthetic peptide, marketed as thymalfasin. Goldstein and Goldstein's 2009 review in Expert Opinion on Biological Therapy describes it as approved in more than 35 countries for hepatitis B and C and as an immune stimulant and adjuvant, with late-stage testing at that time in the United States and Europe for hepatitis C and stage IV melanoma, and with reported applications explored in septic shock, acute respiratory distress syndrome, peritonitis, cytomegalovirus infection, tuberculosis and lung infection in critically ill patients. Our dedicated page covers it in depth: thymosin alpha-1.

Thymosin beta-4 belongs to a different family altogether. It is a 43-amino-acid, naturally occurring actin-sequestering peptide. The 2012 review by Goldstein, Hannappel, Sosne and Kleinman describes its role in repair and regeneration: released by platelets, macrophages and other cell types after injury, binding actin, promoting cell migration and angiogenesis, and reducing apoptosis, inflammation and scarring. Its research interest is tissue repair rather than T-cell maturation, and the commonly sold fragment TB-500 is a partial sequence of it, not the full peptide. See our thymosin beta-4 guide.

Thymalin sits outside both categories. It is an extract rather than a synthesized molecule, its evidence base is national rather than international, and its regulatory status reflects that.

The shared vocabulary is a historical accident of 1970s nomenclature. Reading a thymosin alpha-1 trial and attributing its findings to thymalin is a category error.

Inside Russia, thymalin is a registered pharmaceutical given by injection under medical supervision for indications related to immune dysfunction. Outside Russia the picture is entirely different. We found no marketing authorization for thymalin from the FDA, the EMA, the MHRA, Health Canada or the TGA. In those jurisdictions it is not a medicine, and any product bearing the name is typically offered as a research chemical not approved for human use.

That has several concrete implications. There is no regulated manufacturing standard behind internationally sold material, so sterility, endotoxin content, peptide identity and batch consistency are unverified unless a buyer commissions independent testing. Because the original product is derived from bovine tissue, animal-origin material also raises sourcing and biological safety questions that synthetic peptides do not, including heterologous protein immunogenicity.

Legal status varies by country and can change. In some jurisdictions possession for personal research use is tolerated while sale for human administration is not; in others import itself is restricted. Readers should check their own national rules rather than assume. Competitive athletes should additionally check with their anti-doping authority before assuming any immunomodulatory peptide is permitted, since class-based prohibitions can capture substances that are not individually named.

Finally, a note on marketing. Thymalin is frequently promoted online with language about reversing immune aging, and that framing goes far beyond what the published record supports. Klow Peptide does not sell thymalin and this guide contains no purchase links.

Medical disclaimer. Nothing in this article is medical advice, and no part of it should be read as an endorsement of use. Preclinical and non-randomized findings do not establish safety or effectiveness in humans. Speak with a licensed physician or pharmacist about any decision affecting your health.

Russian clinical practice spanning several decades is often presented as evidence that thymalin is well tolerated. That experience is real, but it does not amount to a pharmacovigilance database that an international regulator would accept, and it does not translate to unregulated material administered without supervision.

The categories of risk that deserve attention are straightforward. Any injected preparation derived from animal tissue carries a potential for hypersensitivity and allergic reactions to heterologous protein. Any injection carries risks of local reaction and infection, amplified when the product is not sterile-manufactured to pharmaceutical standards. And any compound that modulates immune function raises questions in people with autoimmune disease, in transplant recipients, in those receiving immunosuppressants or checkpoint inhibitors, and in people with active malignancy, where the direction of any immunological effect is simply not characterized.

The honest list of unknowns is longer than the list of knowns:

• No published human pharmacokinetics, half-life or bioavailability data in the indexed international literature.
• No characterized dose-response relationship, and therefore no basis on which anyone could responsibly suggest an amount.
• No batch-to-batch composition standard that applies to internationally sold material.
• No interaction studies with immunosuppressants, biologics or vaccines.
• No data supporting use in pregnancy, breastfeeding or in children.
• No long-term safety follow-up in a population outside Russia.

Because of that, this guide gives no dosage, no cycle length, no route and no stacking suggestion, and we would treat any source that does so with suspicion. The absence of reported harm in a literature that was never designed to detect harm is not a safety finding.

Thymalin is a legitimate piece of pharmacological history. It came out of a serious Soviet research program, it sits in a biologically plausible space (thymic involution and immunosenescence are genuine features of aging), and it produced a useful spin-off in the isolated dipeptides EW and KE, which continue to be studied as candidate regulators of immune gene expression.

At the same time, the claims attached to it in consumer channels run far ahead of the data. The headline mortality findings come from a non-randomized long-term observation led by the product's own developers. The COVID-era comparison is a single non-randomized report in a Russian-language journal. The mechanistic work is largely computational or in vitro. Nothing in that package constitutes proof of clinical benefit, and the size of the reported effects is itself a reason for skepticism rather than excitement.

A useful way to position it: if you want a thymus-derived peptide with an internationally reviewed evidence base and real regulatory approvals in specific indications, that compound is thymosin alpha-1, not thymalin. If your interest is tissue repair rather than immunity, the relevant literature is the thymosin beta-4 literature. If your interest is the Khavinson bioregulator framework as a whole, the pineal side of that program is covered in our Epithalon guide, and the same evidence cautions apply there.

Thymalin may eventually be validated, partially validated, or abandoned. Which of those happens depends on whether anyone runs the randomized, registered, independently conducted trials that sixty years of enthusiasm have not yet produced. Until then, the accurate statement is not that thymalin works and not that it fails, but that we do not know, and that the published record is too weak to support personal use.

This article is for educational purposes only. It is not medical advice and does not recommend use of thymalin. Consult a qualified healthcare professional before acting on any health information.